source
- FDA cites Baxter’s inadequate oversight after repeated GMP violations at multiple plantsThe U.S. Food and Drug Administration has issued a warning letter to Baxter International, saying the company's leadership has failed to provide adequate oversight of its drug manufacturing operati…
- Mark Cuban’s Cost Plus Drugs plans to enter custom rare-disease drug marketMark Cuban says his company Cost Plus Drugs will expand beyond generic medicines into the custom‑made rare disease space. The firm, which currently buys generic drugs and sells them directly to con…